Characterization of the Synergistic Inhibition of I(K(erg)) and I(K(DR)) by Ribociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor

Ribociclib (RIB, LE011, Kisqali(®)), an orally administered inhibitor of cyclin-dependent kinase-4/6 (CDK-4/6) complex, is clinically effective for the treatment of several malignancies, including advanced breast cancer. However, information regarding the effects of RIB on membrane ion currents is l...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Pin-Yen, Chang, Wei-Ting, Wu, Sheng-Nan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7663338/
https://www.ncbi.nlm.nih.gov/pubmed/33138174
http://dx.doi.org/10.3390/ijms21218078

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7663338/
https://www.ncbi.nlm.nih.gov/pubmed/33138174
http://dx.doi.org/10.3390/ijms21218078

Ejemplares similares